TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Unsafe treatment decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of sustained ventricular tachyarrhythmia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Medicare reimbursements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of suture abscess formation
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of erythema and edema
Endpoint domain: Adverse events/effects
Primary endpoint: CRP decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of action of rocuronium (duration TOF 0.9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of action of cisatracurium (duration TOF 0.9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postdelivery nausea or vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: LDL/HDL-cholesterol improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ADAS-Cog-C scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission (lack of disease activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: active disease persistence or recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average fracture healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of cases rated as excellent and good
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: stabilization of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing time of autologous skin pulp grafting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum levels of trace elements (zinc, selenium, phosphorus, magnesium, copper, iron, calcium, cadmium)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aortic valve area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Indexed aortic valve area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rotational stability of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft failures
Endpoint domain: Adverse events/effects
Primary endpoint: 5-year cumulative diagnosis rate of metastatic melanoma
Endpoint domain: Mortality/survival
Primary endpoint: reduced treatment failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Time (GT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cardiovascular SOFA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resolution of cardiovascular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Onset of hematologic organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risk of retinopathy progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Risk of nephropathy progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glycosylated hemoglobin (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extra distance walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased comfortable walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extra fast speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritoneal appearance rate of interleukin (IL)-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peritoneal appearance rate of cancer antigen 125
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concentration of effluent macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymphocyte ascorbate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte glutathione concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to first follow-up appointment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reduction on the VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRTEE improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood pressure and heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Graft flow fraction (GFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peripheral Neuritis
Endpoint domain: Adverse events/effects
Primary endpoint: floor walking velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in BPH symptoms (I-PSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in maximum urinary flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sexual function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: days of maternal hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: maternal hospital expenses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite outcome of death or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Time to first hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: cumulative probability of failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vision reduction ≥2 Snellen lines
Endpoint domain: Adverse events/effects
Primary endpoint: Accumulation of lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ability to keep up with usual activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Serum levels of VEGF, BDNF and NGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean time oxygen saturation (SpO2) less than 94%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time shin temperature >36°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of refractory ascites and/or pleural effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative serum concentration of reduced-state albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of active second stage labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: mean physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean aerobic fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total arrhythmia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disability level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy Density (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay in the acute unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Gastrointestinal/genitourinary adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: sleep onset delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: night wakings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall CGI‐S improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Abstinence rates at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: personal performance scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: median motility index of phase III in the proximal duodenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: duration of phase III in the distal duodenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: duration of the migrating motor complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: onset of block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for general anaesthesia for inadequate block
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete vaccination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of opioid use disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average hair count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disabling/fatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: levels of anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of both leakage and fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BCVA gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness Handicap Inventory (DHI) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Residual dizziness duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aspiration of water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical effort of lifeguards
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction in total wound care cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in the use of split‐thickness skin grafts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement on ADHD symptom measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pulse rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Total Symptom Score (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of continued diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of diarrheal episodes lasting > 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in serum hyaluronan concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ASCVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve (AUC) of miRNA‐933
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum voluntary isometric contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 2-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: effectiveness of CT-localized scalp round-needling therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrent bleeding episodes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: satisfactory vaccine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-H3N2 antibody fold increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-B-Yamagata antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hip fracture occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Prosthesis success rate
Endpoint domain: Mortality/survival
Primary endpoint: Blood pressure (BP) response during seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate (HR) response during seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate pressure product (RPP) increase during seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of MASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food-induced asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severity of asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity associated with food-induced asthma
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of developing iatrogenic hyponatremia
Endpoint domain: Adverse events/effects
Primary endpoint: VAS scores in activity state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of morphine consumed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence rates of nausea, vomiting, and pruritus
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital admission frequency
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Activities of daily living index scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Stone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lithotripsy and operation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dilatation and stone access time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 24-hour systolic BP variability (BPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: comorbid depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive CST result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gap formations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microleakage tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: penile curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plaque size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Index of Erectile Function score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: L-selectin expression on neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: L-selectin expression on lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SRI at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density (BMD) of lumbar spine and femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage heavy drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of apoptotic lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of necrotic lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of apoptotic neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time required for the SMNSV technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: frequency of nocturnal voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perceived health risks (PHR) for other cancers, heart disease, stroke, and risk for addiction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cord-blood triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of SBP responder patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients who quit smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection requiring intravenous antibiotic therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Unplanned reoperations with explantation
Endpoint domain: Adverse events/effects
Primary endpoint: Discussion of feeding options with healthcare provider
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: 2‐ through 24‐hour sustained pain‐free response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of reflux episodes > 5 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adequacy of ectocervical smears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAPAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IO access score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional recovery at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Löe-Silness GI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Body core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leptin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Probability of complete remission without steroids at month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of colectomy at month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diarrheal incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Diarrheal prevalence
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in body condition score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contraception initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Fetal body weight at 36 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotective hemagglutination inhibition (≥ 1:40)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Well-tolerated vaccinations
Endpoint domain: Adverse events/effects
Primary endpoint: Cystometrogram baseline pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Valsalva leak point pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Volume and pressure measurements at maximum cystometric capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incremental cost-effectiveness of ICD therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Calcium balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postoperative endometritis
Endpoint domain: Adverse events/effects
Primary endpoint: composite end point of death, MI, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: improvements in hand function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V,NEP0.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Nesiritide compared to NTG
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum postdose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed for arranging teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three-fold rise in serum antirotavirus IgA antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of ipsilateral local recurrence as first site of treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Forearm blood flow response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: target vessel MI
Endpoint domain: Mortality/survival
Primary endpoint: peak oxygen uptake per kilogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes